OncoMatch/Clinical Trials/NCT06121180
Study of Cemiplimab Plus Ziv-Aflibercept for Subjects With Metastatic Uveal Melanoma
Is NCT06121180 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies multiple treatments including ZIV-Aflibercept and Cemiplimab for metastatic uveal melanoma.
Treatment: ZIV-Aflibercept · Cemiplimab — The goal of this clinical research study is to find out if Cemiplimab plus Ziv-Aflibercept is safe and effective in treating your condition of metastatic (spread to other parts of your body) uveal melanoma. This research study will test the study drugs to see if the combination of Cemiplimab plus Ziv-Aflibercept can make tumors shrink or stop growing.
Check if I qualifyExtracted eligibility criteria
Cancer type
Melanoma
Biomarker criteria
Allowed: BRAF V600 mutation
Patients with BRAF V600 mutant melanoma must have previously received BRAF targeted therapy for metastatic melanoma and later experienced disease progression. Patients who refuse or decline to receive BRAF targeted therapy or prefer to delay or were intolerant of BRAF targeted therapy are eligible
Disease stage
Required: Stage AJCC STAGE IV, ADVANCED/INOPERABLE STAGE III (AJCC)
Metastatic disease required
This includes AJCC stage IV or advanced/inoperable stage III.
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Must have received: anti-PD-1 therapy (nivolumab, pembrolizumab) — metastatic melanoma
must have previously received anti-PD1 immunotherapy (nivolumab or pembrolizumab) as monotherapy or in combination and later experienced disease progression
Cannot have received: VEGF inhibitor (bevacizumab, aflibercept)
no prior therapy with bevacizumab, aflibercept
Cannot have received: anti-PD-1 therapy (cemiplimab)
no prior therapy with...cemiplimab
Lab requirements
Blood counts
Patients must have normal organ and marrow function as defined in protocol.
Kidney function
Patients must have normal organ and marrow function as defined in protocol.
Liver function
Patients must have normal organ and marrow function as defined in protocol.
Cardiac function
Ejection fraction (EF) from baseline echocardiogram must be within the institutional limits of normal as determined by the reading cardiologist.
Patients must have normal organ and marrow function as defined in protocol. Ejection fraction (EF) from baseline echocardiogram must be within the institutional limits of normal as determined by the reading cardiologist.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- The Angeles Clinic and Research Institute · Los Angeles, California
- Moffitt Cancer Center · Tampa, Florida
- University of Chicago Medical Center · Chicago, Illinois
- Northwell Health Center for Advanced Medicine · New Hyde Park, New York
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify